Sepsis and septic shock (Q59708886)

1

object named as

Richard S Hotchkiss

0 references

Lyle L Moldawer

2

object named as

Lyle L Moldawer

0 references

author name string

Steven M Opal

3

0 references

Konrad Reinhart

4

0 references

Isaiah R Turnbull

Nature Reviews Disease Primers

5

0 references

language of work or name

English

0 references

publication date

30 June 2016

0 references

published in

0 references

volume

2

0 references

page(s)

16045

0 references

exact match

https://scigraph.springernature.com/pub.10.1038/nrdp.2016.45

0 references

cites work

The ancient riddle of sigma eta psi iota sigma (sepsis).

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

The ACCP-SCCM consensus conference on sepsis and organ failure.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

The biology of cachectin/TNF--a primary mediator of the host response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Tolerance, danger, and the extended family

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Sepsis: current dogma and new perspectives

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

31 March 2020

Sepsis and thrombosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Endothelial barrier dysfunction in septic shock

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Acute kidney injury is surprisingly common and a powerful predictor of mortality in surgical sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Improvement in Process of Care and Outcome After a Multicenter Severe Sepsis Educational Program in Spain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Surviving Sepsis Campaign: association between performance metrics and outcomes in a 7.5-year study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Assessing available information on the burden of sepsis: global estimates of incidence, prevalence and mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Surviving sepsis in low-income and middle-income countries: new directions for care and research

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Measuring the global burden of disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Septicaemia in a population-based HIV clinical cohort in rural Uganda, 1996-2007: incidence, aetiology, antimicrobial drug resistance and impact of antiretroviral therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Bacteraemia and mortality among adult medical admissions in Malawi--predominance of non-typhi salmonellae and Streptococcus pneumoniae

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Causes of pediatric mortality and case-fatality rates in eight Médecins Sans Frontières-supported hospitals in Africa

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Epidemiology of sepsis in Victoria, Australia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Marital status and the epidemiology and outcomes of sepsis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

The epidemiology of sepsis in the United States from 1979 through 2000

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Hospital Deaths in Patients With Sepsis From 2 Independent Cohorts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

What is the best method for estimating the burden of severe sepsis in the United States?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Benchmarking the incidence and mortality of severe sepsis in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Regulatory mandates for sepsis care--reasons for caution

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Severe sepsis cohorts derived from claims-based strategies appear to be biased toward a more severely ill patient population

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Declining case fatality rates for severe sepsis: good data bring good news with ambiguous implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Sepsis-associated mortality in England: an analysis of multiple cause of death data from 2001 to 2010.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Sepsis in European intensive care units: results of the SOAP study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Pattern recognition receptors and inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

PAMPs and DAMPs: signal 0s that spur autophagy and immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Modulation of the vascular endothelium during infection--the role of NF-kappa B activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Dysregulation of the angiopoietin-Tie-2 axis in sepsis and ARDS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Role of C5a in inflammatory responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

The harmful role of c5a on innate immunity in sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Protective effects of C5a blockade in sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Functional roles for C5a receptors in sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Complement C5 activation during influenza A infection in mice contributes to neutrophil recruitment and lung injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Inhibition of complement activation alleviates acute lung injury induced by highly pathogenic avian influenza H5N1 virus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Treatment with anti-C5a antibody improves the outcome of H7N9 virus infection in African green monkeys

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Persistent inflammation-immunosuppression catabolism syndrome, a common manifestation of patients with enterocutaneous fistula in intensive care unit

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Persistent inflammation, immunosuppression, and catabolism syndrome after severe blunt trauma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Reactivation of multiple viruses in patients with sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

The late phase of sepsis is characterized by an increased microbiological burden and death rate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Macroscopic postmortem findings in 235 surgical intensive care patients with sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Immature circulating neutrophils in sepsis have impaired phagocytosis and calcium signaling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Dysregulation of in vitro cytokine production by monocytes during sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Innate immune functions of immature neutrophils in patients with sepsis and severe systemic inflammatory response syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Neutrophil extracellular traps in patients with sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Predictive value of monocyte histocompatibility leukocyte antigen-DR expression and plasma interleukin-4 and -10 levels in critically ill patients with sepsis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Immunosuppression in patients who die of sepsis and multiple organ failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Delayed hypersensitivity: indicator of acquired failure of host defenses in sepsis and trauma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Prevention of lymphocyte cell death in sepsis improves survival in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Persistent lymphopenia after diagnosis of sepsis predicts mortality.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Antibiotics improve survival and alter the inflammatory profile in a murine model of sepsis from Pseudomonas aeruginosa pneumonia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Akt decreases lymphocyte apoptosis and improves survival in sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

TAT-BH4 and TAT-Bcl-xL peptides protect against sepsis-induced lymphocyte apoptosis in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Agonistic monoclonal antibody against CD40 receptor decreases lymphocyte apoptosis and improves survival in sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Severe sepsis and septic shock

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Glycocalyx and sepsis-induced alterations in vascular permeability

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Targeting Robo4-dependent Slit signaling to survive the cytokine storm in sepsis and influenza

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Complement Interactions with Blood Cells, Endothelial Cells and Microvesicles in Thrombotic and Inflammatory Conditions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Erythrocyte-derived microvesicles amplify systemic inflammation by thrombin-dependent activation of complement

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Science review: role of coagulation protease cascades in sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Enhanced expression of cell-specific surface antigens on endothelial microparticles in sepsis-induced disseminated intravascular coagulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Inflammation and coagulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

A review of sepsis-induced cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Oxidative stress and mitochondrial dysfunction in sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Interdependence of hypoxic and innate immune responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

The implications and management of septic acute kidney injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Sepsis induces extensive autophagic vacuolization in hepatocytes: a clinical and laboratory-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Beyond Blood Culture and Gram Stain Analysis: A Review of Molecular Techniques for the Early Detection of Bacteremia in Surgical Patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Sepsis definitions: time for change

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Lactate measurements in sepsis-induced tissue hypoperfusion: results from the Surviving Sepsis Campaign database.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Procalcitonin: potential role in diagnosis and management of sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Rapid diagnosis of sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Guidelines for the prevention of intravascular catheter-related infections

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Outcomes in severe sepsis and patients with septic shock: pathogen species and infection sites are not associated with mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

An evaluation of systemic inflammatory response syndrome signs in the Sepsis Occurrence in Acutely ill Patients (SOAP) study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

International study of the prevalence and outcomes of infection in intensive care units

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Antibiotic strategies in severe nosocomial sepsis: why do we not de-escalate more often?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Early goal-directed therapy in the treatment of severe sepsis and septic shock

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

A randomized trial of protocol-based care for early septic shock

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

The "VIP" approach to the bedside management of shock

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Consensus statement of the ESICM task force on colloid volume therapy in critically ill patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Fluid resuscitation in acute medicine: what is the current situation?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Dopamine versus norepinephrine in the treatment of septic shock: a meta-analysis*.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Comparison of Dopamine and Norepinephrine in the Treatment of Shock

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

A Selective V(1A) Receptor Agonist, Selepressin, Is Superior to Arginine Vasopressin and to Norepinephrine in Ovine Septic Shock

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Why have clinical trials in sepsis failed?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

The epidemiology of sepsis during rapid response team reviews in a teaching hospital

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Sepsis guidelines: Clinical practice implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Improving care of the sepsis patient.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Quality of life in adult survivors of critical illness: a systematic review of the literature.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Increased 1-year healthcare use in survivors of severe sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

The symptom burden of chronic critical illness

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Long-term survival, quality of life, and quality-adjusted life-years among critically ill elderly patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Rehabilitation interventions for postintensive care syndrome: a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Long term health-related quality of life in survivors of sepsis in South West Wales: an epidemiological study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Persistent cognitive impairment, hippocampal atrophy and EEG changes in sepsis survivors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Posttraumatic stress disorder in critical illness survivors: a metaanalysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

The impact of critical illness on perceived health-related quality of life during ICU treatment, hospital stay, and after hospital discharge: a long-term follow-up study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Long-term physical outcome in patients with septic shock.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Efficacy and safety of recombinant human activated protein C for severe sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Why activated protein C was not successful in severe sepsis and septic shock: are we still tilting at windmills?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

An extracorporeal blood-cleansing device for sepsis therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

The new normal: immunomodulatory agents against sepsis immune suppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Parallels between cancer and infectious disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Harnessing the biology of IL-7 for therapeutic application

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

IL-7 Restores Lymphocyte Functions in Septic Patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

A comprehensive time-course-based multicohort analysis of sepsis and sterile inflammation reveals a robust diagnostic gene set

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Gene expression profiling in sepsis: timing, tissue, and translational considerations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Development and validation of a novel molecular biomarker diagnostic test for the early detection of sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Genetic predisposition to respiratory infection and sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Assessment of coma and impaired consciousness. A practical scale

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Sir Isaac Newton, sepsis, SIRS, and CARS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Low-dose hydrocortisone therapy attenuates septic shock in adult patients but does not reduce 28-day mortality: a meta-analysis of randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Vasopressin versus norepinephrine infusion in patients with septic shock.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II trial. TCV-309 Septic Shock Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

A double-blind placebo-controlled study of an infusion of lexipafant (Platelet-activating factor receptor antagonist) in patients with severe sepsis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, p

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Methylene blue administration in septic shock: a clinical trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Recombinant Human Activated Protein C for Adults with Septic Shock. A Randomized Controlled Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

A phase I study evaluating the pharmacokinetics, safety and tolerability of an antibody-based tissue factor antagonist in subjects with acute lung injury or acute respiratory distress syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Selenium supplementation for sepsis: a meta-analysis of randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Open randomized phase II trial of an extracorporeal endotoxin adsorber in suspected Gram-negative sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Effect of granulocyte-macrophage colony-stimulating factor on the immune response of circulating monocytes after severe trauma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. CAP Study Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Interferon gamma in trauma-related infections

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Effect of interferon gamma on infection-related death in patients with severe injuries. A randomized, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Interleukin-7 (IL-7) treatment accelerates neutrophil recruitment through gamma delta T-cell IL-17 production in a murine model of sepsis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Interleukin-7 ameliorates immune dysfunction and improves survival in a 2-hit model of fungal sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Mechanisms involved in interleukin-15-induced suppression of human neutrophil apoptosis: role of the anti-apoptotic Mcl-1 protein and several kinases including Janus kinase-2, p38 mitogen-activated protein kinase and extracellular signal-regulated k

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Interleukin-15 increases vaccine efficacy through a mechanism linked to dendritic cell maturation and enhanced antibody titers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Dose-dependent effect of anti-CTLA-4 on survival in sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

T cell Ig mucin-3 promotes homeostasis of sepsis by negatively regulating the TLR response.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Blockade of the T cell immunoglobulin and mucin domain protein 3 pathway exacerbates sepsis-induced immune deviation and immunosuppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

LAG-3 regulates plasmacytoid dendritic cell homeostasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Lymphocyte Activation Gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.45

Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis

31 March 2020

1 reference

12 December 2020

E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators

1 reference

12 December 2020

An overview of clinical studies in healthy subjects and patients with severe sepsis with IC14, a CD14-specific chimeric monoclonal antibody

1 reference

12 December 2020

Effects of N-acetylcysteine on microalbuminuria and organ failure in acute severe sepsis: results of a pilot study

1 reference

12 December 2020

Six areas lead national early immunization drive

1 reference

12 December 2020

Bim siRNA decreases lymphocyte apoptosis and improves survival in sepsis

1 reference

12 December 2020

Treatment of patients with severe sepsis using ulinastatin and thymosin alpha1: a prospective, randomized, controlled pilot study.

1 reference

12 December 2020

N-acetylcysteine for sepsis and systemic inflammatory response in adults

1 reference

12 December 2020

Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections

1 reference

12 December 2020

Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock

1 reference

12 December 2020

1 reference

12 December 2020

Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response

1 reference

12 December 2020

Measuring and predicting long-term outcomes in older survivors of critical illness

1 reference

12 December 2020

Statin therapy in critically-ill patients with severe sepsis: a review and meta-analysis of randomized clinical trials

1 reference

12 December 2020

Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis

1 reference

12 December 2020

Hospital Incidence and Mortality Rates of Sepsis

1 reference

12 December 2020

Rationale and Design of an Adaptive Phase 2b/3 Clinical Trial of Selepressin for Adults in Septic Shock. Selepressin Evaluation Programme for Sepsis-induced Shock-Adaptive Clinical Trial.

1 reference

12 December 2020

Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group

1 reference

12 December 2020